Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on ...

A third trial failure this year for the same experimental neurological drug has led Sage Therapeutics to discontinue ...

Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen, headquartered in Cambridge, Massachusetts, has established itself as a key player in the biopharmaceutical industry, focusing on innovative therapies for neurological conditions.

the Cambridge, Massachusetts-based company said Wednesday in a statement. While that’s a 6% decline from a year earlier, it beat analysts’ estimates. The results could help Biogen start to ...

Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry of ...